Beyond Air (XAIR, Financial) has been granted a new patent by the United States Patent and Trademark Office, providing protection for its innovative approach to delivering gaseous nitric oxide (gNO) to patients. This patent, numbered 12,274,830, specifically addresses treatment for conditions linked to non-tuberculous mycobacteria lung infection.
The patented method involves a unique dosing strategy, which includes administering 200 to 320 parts per million (ppm) of gNO for durations of 10 to 45 minutes, repeated two to five times daily. This regimen is designed to achieve a daily nitric oxide-load of 300 ppm-hours to 900 ppm-hours over a minimum period of two weeks. This development underscores Beyond Air's commitment to enhancing therapeutic approaches for respiratory conditions.
The patent is set to expire on March 12, 2038, providing the company with long-term exclusivity for this treatment method.
